Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study

Table 1

Patient characteristics at baseline.

Baseline characteristics	n = 65
Age (year)	64 (22–85)
<65 years	33 (50.8%)
>65 years	32 (49.2%)
Sex
Men	42 (64.6%)
Women	23 (35.4%)
ECOG
0	38 (58.5%)
1	22 (33.8%)
2	4 (6.1%)
3	1 (1.6%)
Anti-PD-1 antibody
Pembrolizumab	49 (75.4%)
Nivolumab	16 (24.6%)
BRAF status
Mutant	22 (33.8%)
Wild type	43 (66.2%)
Albuminemia
Normal	53 (81.5%)
<35 g/l	2 (3.1%)
Unknown	10 (15.4%)
LDH
< ULN	36 (55.4%)
> ULN	12 (18.4%)
Unknown	17 (26.2%)
Prior systemic therapies
0	36 (55.4%)
1	20 (30.8%)
2	5 (7.7%)
3	3 (4.6%)
4	1 (1.5%)
Prior ipilimumab	14 (21.5%)
Prior BRAF ± MEK inhibitor	18 (27.7%)
Concurrent radiotherapy	12 (18.4%)
Number of metastatic localizations
1	17 (26.2%)
2	22 (33.8%)
3	14 (21.5%)
>3	12 (18.5%)
Brain metastasis	11 (16.9%)

Values are n (%) or median (interquartile range). Abbreviations: ECOG PS, eastern cooperative oncology group performance status; PD-1, programmed cell death protein 1; LDH, lactate dehydrogenase; ULN, upper limit of normal.